iRhythm Q3 2026 net loss widens to $29.85 million
IRTC•iRhythm’s third-quarter 2026 GAAP net loss widened to $29.9 million from a year earlier, while revenue rose 15% to $221.6 million. The company raised FY26 revenue guidance to $890 million–$895 million, including approximately $16 million from VitalConnect.
1. Quarterly results and guidance
iRhythm’s third-quarter 2026 GAAP net loss widened to $29.9 million from a year earlier, while revenue rose 15% year over year to $221.6 million, driven primarily by sustained volume demand. The company increased FY26 revenue guidance to $890 million–$895 million, including approximately $16 million from VitalConnect, whose acquisition closed October 5 and added an FDA-cleared mobile cardiac telemetry offering.
